Search Within

Maria Lia Palomba

Formats
  1. Meeting Abstract (289)
  2. Journal Article (131)
  3. Research Letter (10)
  4. Review (8)
  5. Correspondence (4)
  6. Editorial (3)
  7. Book Section (1)
  8. Conference Paper (1)
  9. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (448)
  2. Department of Medicine (448)
  3. Hematologic Malignancies, Division of (448)
  4. Lymphoma (448)
  5. Hematology-Oncology Fellows (228)
  6. Survivorship Research (209)

More Groups

People
  1. Andrew Zelenetz (143)
  2. Ariela Noy (132)
  3. Paul Hamlin (126)
  4. Gilles Salles (114)
  5. Steven Horwitz (112)
  6. Gunjan Shah (111)

More People

Years
  1. 2025 (19)
  2. 2024 (58)
  3. 2023 (69)
  4. 2022 (39)
  5. 2021 (41)
  6. 2020 (43)

More Years

Publications
  1. Blood (187)
  2. Journal of Clinical Oncology (37)
  3. Hematological Oncology (30)
  4. Blood Advances (19)
  5. Blood Cancer Journal (15)
  6. British Journal of Haematology (14)

More Publications

Publishers
  1. American Society of Hematology (207)
  2. Elsevier Inc. (45)
  3. American Society of Clinical Oncology (38)
  4. Nature Publishing Group (33)
  5. Wiley Blackwell (31)
  6. John Wiley & Sons (14)

More Publishers

Results (448)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • An ongoing pilot study of targeted radioimmunotherapy (131-I apamistamab) conditioning prior to CD19-targeted CAR T-cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma
    Meeting Abstract

    Geyer, M. B.; Cadzin, B.; Hosszu, K.; Senechal, B.; Spross, J. A.; Mark, A.; Desai, A.; Cathcart, E. R.; Palomba, M. L.; Pandit-Taskar, N.
    Blood (2022)

    Fulltext@MSK | Save
  • Outcomes of therapies and resistance mutations following non-covalent Bruton's Tyrosine Kinase inhibitor treatment for patients with chronic lymphocytic leukemia and Richter Transformation
    Meeting Abstract

    Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Jensen, J. L.; Shah, N. N.; Luo, T.; Patel, K.; Bailey, N.; Fakhri, B.; Eyre, T. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation
    Meeting Abstract

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A 3-year follow-up comparison of clinical outcomes from Zuma-5 (axicabtagene ciloleucel) and the international scholar-5 external control cohort in relapsed/refractory follicular lymphoma (R/R FL)
    Meeting Abstract

    Ghione, P.; Palomba, M. L.; Ray, M. D.; Limbrick-Oldfield, E. H.; Owen, J.; Kanters, S.; Bobillo, S.; Ribeiro, M. T.; Jacobson, C. A.; Neelapu, S. S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Predictors and implications of renal injury in large cell lymphoma patients receiving CD19 CAR T cell therapy
    Meeting Abstract

    Boardman, A. P.; Gutgarts, V.; Flynn, J. R.; Devlin, S. M.; Tomas, A. A.; Fein, J. A.; Slingerland, J.; Parascondola, A.; Lin, R. J.; Scordo, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2
    Meeting Abstract

    Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed / refractory Waldenström macroglobulinemia: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Palomba, M. L.; Patel, M. R.; Eyre, T. A.; Jurczak, W.; Lewis, D. J.; Gastinne, T.; Ma, S.; Cohen, J. B.; Patel, K.; Brown, J. R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1XX CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Rivière, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Bermudez, V. P.; Cathcart, E. R.; Liotta, K.; Joseph, J.; more...
    Blood (2022)

    Fulltext@MSK | Save